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Introduction: It is well confirmed that myostatin is a negative regulator of skeletal muscle
mass and implicated in several diseases involved in muscle wasting and cachexia. Skeletal
muscle wasting is an important systemic manifestation of chronic obstructive pulmonary
disease (COPD), while the expression of circulating myostatin in COPD remains unclear. The
aim of this study was to investigate the expression of circulating myostatin and its relationship
with skeletal muscle wasting in COPD.
Methods: Seventy-one patients with stable COPD and sixty age-matched, healthy control
subjects participated in the study. Total skeletal muscle mass (SMM) were calculated according
to a validated formula by using age and anthropometric measurements. Serum levels of myos-
tatin, tumor necrosis factor (TNF)-a and interleukin-6 were determined by ELISA.
Results: Serum myostatin levels were significantly elevated in COPD patients when compared
to controls [(11.85  4.01) ng/ml vs. (7.46  2.21) ng/ml, p < 0.01], while total SMM was signif-
icantly decreased in COPD patients when compared to controls [(20.81  1.74) kg vs.
(27.31  2.18) kg for male, and (11.70  0.56) kg vs. (19.89  1.47) kg for female] (both
p < 0.05). Regression correlation analysis on all COPD patients showed that serum myostatin
levels weren’t significantly correlated with SMM, but correlated with TNF-a levels
(R2 Z 0.042, p Z 0.048). However, when stratified for gender, serum myostatin levels were
correlated inversely both with SMM (R2 Z 0.20, p Z 0.000) and with BMI (R2 Z 0.084,
p Z 0.019) in subgroup of male patients.
Conclusion: This study demonstrates that circulating myostatin levels are elevated in COPD
and related to SMM in male patients, suggesting that myostatin contributes to skeletal muscle
wasting in COPD.
ª 2011 Elsevier Ltd. All rights reserved.0 83062870; fax: þ86 20 83062979.
m (R.-C. Chen).
1 Elsevier Ltd. All rights reserved.
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Skeletal muscle wasting is one of the most important extra-
pulmonary manifestations of chronic obstructive pulmonary
disease (COPD),1 which is recognized as contributing to an
increase in morbidity and decrease in quality of life.2,3
Retrospective studies have demonstrated that skeletal
muscle wasting is associated with an increase in mortality.4
Myostatin, a transforming growth factor-beta superfamily
member, has been well confirmed as a negative regulator of
skeletal muscle mass and mainly expressed in skeletal
muscles,5 while there was also evidence of myostatin
secretion and circulation in animals6 and human blood.7 In
recent years, studies have shown that myostatin is impli-
cated in several diseases involved in muscle wasting and
cachexia.8 More recently, there were several reports
showing that intramuscular myostatin expression acceler-
ated in COPD patients, suggesting that intrumuscular
elevation of myostatin expression could induce muscle
wasting in COPD patients.9 While expression of circulating
myostatin in COPD and whether or not it contributes to
whole-body skeletal muscle wasting in COPD remains
unclear. The previous studies led us to hypothesize that an
increase of myostatin expression in skeletal muscles of
COPD patients may elevate circulating levels, resulting in
muscle wasting of whole body. Therefore, the aims of this
investigation were to evaluate the following questions in
COPD patients: 1) Whether or not the circulating myostatin
is increased; 2) Is the circulating level of myostation
correlated with the total-body skeletal muscle mass (SMM);
and 3) Is the circulating level of myostation correlated with
TNF-a and IL-6, as the latter two were recognized as
systemic cytokines associated with wasting in COPD.
Materials and methodology
Subjects and study design
This was an intersectional comparison study. The study was
approved by the Research Committee of Human Investigation
of Guangzhou Medical College and informed consent was
obtained for each participant during the period from Mar
2007 to Oct 2008. Seventy-one patients with COPD were
enrolled in the study. The diagnosis of COPDwas according to
the criteria of GOLD guidelines.10 Inclusion criteria for COPD
included: 1) ratio of forced expiratory volume in 1st second
to forced vital capacity (FEV1/FVC) < 70% after bronchodi-
lator; 2) FEV1<80% of the predicted value; and 3) the
reversibility testing with inhalation of b2-agonist (200 mg
salbutamol) showing to be<12% increase in FEV1; 4) clinically
stable for at least 3 months; 5) ex-smokers with abstaining
from smoking for at least 3 years. The exclusion criteria
were: 1) Patients with major co-morbidities or concomitant
diseases that might alter nutritional status or muscle func-
tions were excluded from the study. These co-morbidities
included hepatic cirrhosis, uncontrolled diabetes, chronic
renal failure, thyroid disease, neoplasm, and cancer, etc.;
some co-morbidities such as osteoporosis,mild andmoderate
essential hypertension were not exclude from the study for
these co-morbidities had no effects on nutritional status. 2)
Patients receiving nutritional support therapy; 3) Patientsunwilling to participate or sign the informed consent. Sixty
control subjects were recruited from the health check-up
department of the hospital. The inclusion criteria were: 1)
no history of major or chronic disorders; 2) with normal
pulmonary function; 3) never smoked or had abstained from
smoking for more than 10 years.
The medical treatment of the patients at the time of the
study mainly included inhaled bronchodilator therapy in the
form of long-acting agonists and/or anti-cholinergic agents.
In addition, 85% of the patients were on inhaled corticoste-
roids (400e800 mg budesonide equivalent dose/day). None of
the patients was on regular systemic corticosteroids.
Pulmonary function evaluation
All patients and control subjects underwent spirometry and
reversibility testing in COPD patients with inhalation of
a short acting b2-agonist of salbutamol (200 mg).
Skeletal muscle mass
Total skeletal muscle mass (SMM) was evaluated according
to a validated formula11 by using age and anthropometric
measurements; the latter included body height (in m) and
skinfold corrected limb circumferences [upper arm, thigh,
and calf girths (CAG, CTG, and CCG, respectively; in cm)].
Circumference measurements were made in the plane
orthogonal to the long axis of the body segment being
measured. Skinfold thickness of the triceps, thigh, and mid-
calf were measured by using a skinfold caliper; circumfer-
ences of the mid-upper arm, mid-thigh, and mid-calf were
measured with a flexible measuring tape, respectively,
according the standardized anatomic locations.11 The limb
circumferences (Climb) were corrected for subcutaneous
adipose tissue thickness. The skinfold caliper measurement
(S) was assumed to be twice the subcutaneous adipose
tissue thickness. Corrected muscle circumferences (Cm)
were thus calculated as CmZ ClimbpS.12 The formula was
as follows:
SM ðkgÞZHt  ð0:00744  CAG2 þ 0:00088  CTG2
þ0:00441  CCG2Þ þ 2:4  sexþ 0:048  age þ race þ 7:8
Where sexZ 0 for female and 1 for male, raceZ 2.0 for
Asian patients, according to the research by Lee et al.11
Measurements of serum myostatin, TNF-a, and IL-6
levels
For each subject, peripheral venous blood was drawn
between 7:00 and 8:00 am after fasting since 9:00 pm the
previous night. After centrifugation at 1000 rpm for 5 min at
4 C, serum samples were collected and subsequently
stored at 80 C until analyzed. Serum myostatin levels
were determined by antibody sandwich enzyme-linked
immunosorbent assay (ELISA) kits (BioVendor Laboratory
Medicine, Inc.), TNF-a by ELISA kits (Quantikine; R&D
Systems, Minneapolis, MN), and IL-6 by ELISA kits (Bender
Med Systems).
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Level of daily life physical activity (PA) was assessed by
using a PA questionnaire adapted for the elderly in China.
The original questionnaire on habitual PA consisted of 19
items, scored the past 3 year’s household activities, sports
activities, and other physically active leisure-time activi-
ties and gave an overall score.13,14 The subjects were asked
to describe type of the PA, hours per week spent on it, and
period of the year in which the PA was normally performed.
There is an appendix for PA score criteria.
Statistical analyses
Statistical analysis was performed by using SPSS 13.0 (SPSS
Inc., Chicago, IL, USA) statistical package for windows and
Graphpad Prism v. 5 (Graphpad software INC., San Diego,
CA, USA). Data were expressed as mean  Sd. Student’s t
test was used for comparisons of unpaired parameters
between patients and controls. Linear regression correla-
tion analysis was used to determine the relationship of
serum myostatin levels with other parameters. The level of
statistical significance was set as p < 0.05.
Results
Characteristics of subjects
Clinical characteristics of all the patients with COPD and
healthy controls are summarized in Table 1. Spirometric
test showed the average FEV1 was (37.76  14.93)% pre-
dicted, indicating that majority of the COPD patients were
with severe airflow limitation. The severity distribution
stratified by GOLD criteria were 13, 28 and 30 cases in GOLD
stages II, III and IV respectively. There was no significant
difference between patients and controls in terms of age,
while a significant difference was observed in BMI between
the two groups. Among all the COPD patients, 53 ones
(74.65%) had malnutrition, as defined by BMI less than
21 kg/m2.15Table 1 General characteristics of COPD patients and controls
COPD (n Z 70)
Sex, M (%) 54 (76%)
Age (years) 65.17  6.79
BMI (kg/m2) 19.36  3.31
FEV1%pred (%) 37.76  14.93
FEV1/FVC (%) 43.97  12.44
PO2 (mmHg) 79.81  4.66
PCO2 (mmHg) 39.31  4.20
PH 7.40  0.30
Smoking (packa years) 27.92  22.46
PA score (score) 5.25  1.28
BMI Z body mass index; FEV1 Z forced expiratory volume at 1 s; FV
PA Z daily life physical activity; PO2 Z oxygen partial pressure; PCO
The significant differences are vs. controls.
a chi-square value; the others in the column all represent t values.Skeletal muscle mass
Total body SMM was significantly decreased in patients as
compared with controls, with regards to both its absolute
value and its percentage of body weight, as shown in Table
2. Anthropometric measurements for limb circumferences
and local skeletal muscles mass such as CAG, CTG and CCG
were all significantly decreased in patients as compared
with controls (Table 2).
Serum levels of myostatin, TNF-a and IL-6
The mean levels of serum myostatin were significantly
elevated in COPD patients when compared to controls
[(11.85  4.01) ng/ml vs. (7.46  2.21) ng/ml, p < 0.001],
so were serum levels of TNF-a [(6.92  2.02) pg/ml vs.
(4.80  3.45) pg/ml, p < 0.001], as shown in Fig. 1A and B,
respectively. However, there was no significant difference
in IL-6 levels between the two groups [(1.41  0.37) pg/ml
vs. (1.34  0.70) pg/ml, p Z 0.19]. Among patients with
COPD, there was no significant difference in serum myo-
statin levels between the steroid-naive patients and those
on inhaled steroids [(10.17  3.24) ng/ml vs. (12.18  4.15)
ng/ml, p Z 0.08].
Correlations
Regression correlation analysis showed that serum myo-
statin levels were correlated neither with total-body SMM,
nor with BMI in COPD group, but correlated with serum TNF-
a levels (R2 Z 0.042, p Z 0.048) in COPD group (Fig. 2).
However, when stratified for gender, serum myostatin
levels were inversely correlated both with total SMM
(R2 Z 0. 20, p Z 0.000) and with BMI (R2 Z 0.084,
p Z 0.019) in COPD male patients, as shown in Fig. 3a and
b, respectively; an inverse correlation was also observed
between serum TNF-a levels and SMM in COPD male
patients (R2 Z 0. 068, p Z 0.032).
In addition, total-body SMM was significantly correlated
with BMI both in COPD group (R2 Z 0.372, p Z 0.000), and
in normal subjects (R2Z 0.185, pZ 0.000). When stratified.
Control (n Z 60) Statistics P value
21 (35%) 22.40a 0.000
63.98  5.77 1.08 0.282
22.60  2.23 6.44 0.000
97.10  8.90 26.99 0.000
88.52  8.41 23.56 0.000
98.75  1.30 30.51 0.000
36.83  0.64 4.52 0.000
7.39  0.10 0.807 0.421
1.30  50.9 8.98 0.000
7.97  1.21 12.45 0.000
C Z forced vital capacity; %pred Z percent of predicted value;
2 Z carbon dioxide partial pressure.
Table 2 Anthropometric measurements in COPD patients and controls.
Sex COPD patients Controls t value P value
Age (years) M 65.76  7.38 65.14  5.90 0.38 0.71
F 63.29  4.09 63.36  5.67 0.048 0.95
BMI (kg/m2) M 20.00  3.31 23.35  1.63 4.40 0.000
F 17.31  2.38 22.20  2.43 7.03 0.000
CAG (cm) M 17.62  1.88 24.27  2.67 12.17 0.000
F 14.90  1.22 17.05  1.79 5.24 0.000
CTG (cm) M 30.46  3.04 42.79  2.26 19.14 0.000
F 29.76  2.04 36.13  3.32 7.32 0.000
CCG (cm) M 23.93  1.50 28.53  1.40 10.77 0.000
F 21.60  3.17 26.03  2.08 7.06 0.000
SMM (kg) M 20.81  1.74 27.31  2.18 12.24 0.000
F 11.70  0.56 19.89  1.47 22.17 0.000
SMM/Wt%
(%)
M 38.94  4.21 41.81  3.49 3.01 0.004
F 28.81  2.92 36.76  3.77 8.57 0.000
CAGZ skinfold corrected upper-arm girth; CCGZ skinfold corrected calf girth; CTGZ skinfold corrected thigh girth; SMMZ total-body
skeletal muscle mass; Wt Z weight.
The significant differences are vs. controls.
Figure 1 Serum levels of myostatin and TNF-a in COPD
patients and controls. A: Serum myostatin levels were signifi-
cantly elevated in patients relative to controls; B: Serum TNF-
a levels were significantly elevated in patients when compared
to controls.
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higher, with R2 of 0.749 in female and 0.740 in male COPD
patients, respectively, and 0.329 in female and 0.235 in
male control subjects, respectively (all p Z 0.000).
Discussion
In the present study, we analyzed serum myostatin levels in
71 patients with COPD and 60 control subjects. Our analysis
yielded two main findings: (1) serum myostatin levels were
significantly elevated in patients with COPD as compared
with healthy controls. (2) The elevated myostatin levels
were correlated inversely with total-body SMM and BMI in
male COPD patients, while positively with TNF-a levels in
all of the COPD patients. As far as we know, there were no
reports about the relationship between serum myostatin
and SMM in COPD patients in the previous studies.
In the present study, we evaluated total-body SMM
according to a formula developed by Lee et al.11 Our data
showed that the total SMM was significantly correlated withFigure 2 Correlation between serum myostatin and
TNF-a levels in patients with COPD (n Z 71). R2 Z 0.042,
pZ 0.048.
Figure 3 A: Inverse correlation between serum myostatin
levels and total SMM in male patients with COPD (n Z 54).
R2 Z 0.200, p Z 0.000. B: Inverse correlation between serum
myostatin levels and BMI in male patients with COPD (nZ 54).
R2 Z 0.084, p Z 0.019.
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idity of the formula. Though we had tried all efforts to
minimize the impact of co-morbidities, nutritional depletion
were not avoidable for the patients; total-body SMM were
significantly decreased in the patients as compared with
controls, with regards to both its absolute value and its
percentage of body weight so was BMI. The data was
consistent with recent reports that skeletal muscle wasting
and malnutrition were common and substantial in COPD
patients.16,17 The results also showed that serum myostatin
levels were significantly increased in COPD patients relative
to controls. Myostatin is a new member of transforming
growth factor-beta superfamily and first reported in 1997 by
McPherron et al.18 Since its discovery, myostatin has quickly
been attracted much attention as a key regulator of skeletal
muscle mass in both animals19 and humans.20 Recent studies
have shown that myostatin is implicated in several diseases
involved in muscle wasting and cachexia.21,22 Our study
result that serum myostatin was significantly elevated in
COPD patients was consistent with the report that myostatin
mRNA levels andprotein levelswereelevated in quadriceps23
and diaphragm24 of COPD patients, respectively. Moreover,
our data showed that serummyostatin levelswerecorrelated
inversely with total-body SMM in male COPD patients. Thesimilar study result showed that both the serum and intra-
muscular concentrations ofmyostatin were increased in HIV-
infected men with weight loss compared with healthy men
and correlated inversely with fat-free mass index in the
patients.25 These data support our hypothesis that serum
levels of myostatin are consistent with those of gene
expression in skeletal muscles and demonstrate that circu-
lating myostatin may be associated with postnatal muscle
wasting in body. In addition, our study showed that serum
myostatin levels were even higher in the COPD patients with
malnutrition than those with normal BMI, and correlated
inverselywith BMI inmaleCOPDpatients. Similarly, Schulte26
reported that serum myostatin-immunoreactive protein
levels were elevated in physically frail women and inversely
correlated with lean mass. Yarasheski27 reported that
circulating levels ofmyostatin-immunoreactive proteinwere
increased in elderly persons with weight loss. Together with
these data, we suggest that circulating myostatin may also
contribute to weight loss in COPD patients. Our hypothesis
was supported by important messages from recent
researches that myostatin cascade was involved not only in
muscle atrophy but also in cachexia in mammalian,28,29 and
that systemic over-expression of myostatin in adult mice
induced profound muscle and fat loss similar to that seen in
human cachexia syndromes.30 Our findings, together with
the previous reports of the association between elevated
serum myostatin and lean muscle mass indicate a tight
linkage of the circulating myostatin with skeletal muscle
wasting and weight loss in COPD. However, the non-signifi-
cant correlation of serummyostatin levels with SMM and BMI
in female COPD patients was inconsistent with the above
findings. The potential explanation could be the small
sample size of female patients in our study.
With the evidence of elevation of intramuscular myo-
statin in COPD and our study result of elevation of circu-
lating myostatin, we can conclude that myostatin is up-
regulated in patients with COPD. There have been several
reports concerning the risk factors related to up-regulation
of intramuscular myostatin. The reported risk factors
included cigarette smoking, muscle unloading and disuse,
systemic corticosteroid treatment, and chronic
infection.31e35 Very recently, Hayot et al.36 reported an
induction of myostatin expression in muscles of rats
exposed to chronic hypoxia and demonstrated that myo-
statin up-regulation was associated with the skeletal
muscle response to hypoxic stimuli. It is well known that
the chronic progression of COPD is associated with recur-
rent infection during exacerbation periods. In severe COPD,
chronic hypoxia, decreased physical activity and muscle
disuse, as well as systemic corticosteroid treatment during
acute exacerbation are commonly encountered. This means
that COPD patients have the risk factors mentioned above
to stimulate myostatin over-expression. In our study, ABG
analysis showed a varying degree of hypoxia in COPD
patients; PA scores proved a decreased physical activity in
COPD patients. These findings in our study are consistent
with the risk factors associated with myostatin over-
expression in muscles. We thus speculate that the intra-
muscular elevation of myostatin may be the source of
elevation of circulating myostatin, resulting in a whole
body of muscle wasting in COPD patients. Our speculation
was supported by the study result that cardiac-specific
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circulating levels of myostatin by 3- to 4-fold, resulting in
a reduction in weight of whole-body muscles of rats with
heart failure.37 Moreover, the speculation was further
supported by recent research evidences that resistance
training could cause a significant decrease in serum myo-
statin levels and increase in muscle mass in both COPD
patients and healthy men.38e40
There have also been reports on the relationship of
elevated TNF-a levels with myotrophy. Our data also
showed that serum TNF-a levels were elevated and corre-
lated with myostatin levels in COPD group. This finding was
consistent with the study results by Lenk et al.41; they
showed that TNF-a mRNA levels were increased and
correlated positively with myostatin expression in skeletal
muscles of chronic heart failure animals, moreover, they
found that TNF-a could induce the expression of myostatin
in differentiated C2C12 cells. TNF-a is a pleiotropic cyto-
kine classically described as playing a central role in the
pathophysiology of COPD.42,43 TNF-a is once named
cachectin owing to its ability to induce tissue depletion and
inflammatory weight loss.44e46 Currently, there were
accumulating evidences suggesting that TNF-a plays an
important role in skeletal muscle wasting in a number of
systemic diseases including sepsis, COPD, cancer, and
etc,47e49 as TNF-a is involved in the development of
muscular abnormalities resulting in loss of skeletal muscle
mass and function.50,51 Earlier study showed that circu-
lating TNF-a levels were significantly higher in COPD
patients with weight loss when compared to controls, and
that the elevated TNF-a levels were correlated with BMI in
the patients.52 Recent study found that the elevated TNF-
a levels were correlated inversely with SMM (determined by
creatinine-height index) in patients with COPD.53 In
accordance with the findings, our data showed an inverse
correlation of serum TNF-a levels with total-body SMM in
male COPD patients. Together with these literatures and
our study results, we suggest that the elevated TNF-a might
stimulate expression of myostatin in COPD, leading to
a more significant skeletal muscle wasting in COPD.
However, further studies need to investigate the exact
relationship of TNF-a with myostatin and determine
whether it is another inducer of myostatin in COPD. With
regards to IL-6, our data failed to find out its elevation in
COPD patients, which was in accordance with the one
reported by Karadag et al.54 However, Yende et al.55
showed that IL-6 levels were significantly increased in
COPD patients and correlated to body weight. The likely
explanation for the inconsistence was that the patients in
our study has been in stable stage for more than 3 months,
thus the serum levels of IL-6 may be not significantly
elevated. Further study should be taken to give the exact
explanation, but we didn’t focus on IL-6 in the study.Limitation of the study
The major limitation of this study was the small sample size
of the female patients with COPD. The conclusion should be
confirmed by further studies in a larger population of
female patients; although limited, is enough to gain some
understanding of the myostatin in patients with COPD.Conclusions
In summary, our study data demonstrates that circulating
myostatin levels were significantly elevated in COPD
patients, and that the elevated myostatin levels were
correlated inversely with total-body SMM and BMI in COPD
male patients. We conclude that the elevated circulating
myostatin may contribute to muscle wasting and weight
loss in patients with COPD.Conflict of interest statement
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